Functional brain connectivity phenotypes for schizophrenia drug discovery

Neil Dawson, Brian J Morris, Judith A Pratt

Research output: Contribution to journalArticle

14 Citations (Scopus)
68 Downloads (Pure)

Abstract

While our knowledge of the pathophysiology of schizophrenia has increased dramatically, this has not translated into the development of new and improved drugs to treat this disorder. Human brain imaging and electrophysiological studies have provided dramatic new insight into the mechanisms of brain dysfunction in the disease, with a swathe of recent studies highlighting the differences in functional brain network and neural system connectivity present in the disorder. Only recently has the value of applying these approaches in preclinical rodent models relevant to the disorder started to be recognised. Here we highlight recent findings of altered functional brain connectivity in preclinical rodent models and consider their relevance to those alterations seen in the brains of schizophrenia patients. Furthermore, we highlight the potential translational value of using the paradigm of functional brain connectivity phenotypes in the context of preclinical schizophrenia drug discovery, as a means both to understand the mechanisms of brain dysfunction in the disorder and to reduce the current high attrition rate in schizophrenia drug discovery.

Original languageEnglish
Pages (from-to)169-177
Number of pages9
JournalJournal of Psychopharmacology
Volume29
Issue number2
Early online date7 Jan 2015
DOIs
Publication statusPublished - 1 Feb 2015

Fingerprint

Drug Discovery
Schizophrenia
Phenotype
Brain
Rodentia
Neuroimaging
Pharmaceutical Preparations

Keywords

  • EEG
  • fMRI
  • default mode network
  • graph theory
  • genetic risk factors
  • hippocampal-prefrontal connectivity
  • thalamic connectivity
  • drug discovery

Cite this

@article{38906229fca14d53927ef4317b7bb4f4,
title = "Functional brain connectivity phenotypes for schizophrenia drug discovery",
abstract = "While our knowledge of the pathophysiology of schizophrenia has increased dramatically, this has not translated into the development of new and improved drugs to treat this disorder. Human brain imaging and electrophysiological studies have provided dramatic new insight into the mechanisms of brain dysfunction in the disease, with a swathe of recent studies highlighting the differences in functional brain network and neural system connectivity present in the disorder. Only recently has the value of applying these approaches in preclinical rodent models relevant to the disorder started to be recognised. Here we highlight recent findings of altered functional brain connectivity in preclinical rodent models and consider their relevance to those alterations seen in the brains of schizophrenia patients. Furthermore, we highlight the potential translational value of using the paradigm of functional brain connectivity phenotypes in the context of preclinical schizophrenia drug discovery, as a means both to understand the mechanisms of brain dysfunction in the disorder and to reduce the current high attrition rate in schizophrenia drug discovery.",
keywords = "EEG, fMRI, default mode network, graph theory, genetic risk factors, hippocampal-prefrontal connectivity, thalamic connectivity, drug discovery",
author = "Neil Dawson and Morris, {Brian J} and Pratt, {Judith A}",
year = "2015",
month = "2",
day = "1",
doi = "10.1177/0269881114563635",
language = "English",
volume = "29",
pages = "169--177",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
number = "2",

}

Functional brain connectivity phenotypes for schizophrenia drug discovery. / Dawson, Neil; Morris, Brian J; Pratt, Judith A.

In: Journal of Psychopharmacology, Vol. 29, No. 2, 01.02.2015, p. 169-177.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Functional brain connectivity phenotypes for schizophrenia drug discovery

AU - Dawson, Neil

AU - Morris, Brian J

AU - Pratt, Judith A

PY - 2015/2/1

Y1 - 2015/2/1

N2 - While our knowledge of the pathophysiology of schizophrenia has increased dramatically, this has not translated into the development of new and improved drugs to treat this disorder. Human brain imaging and electrophysiological studies have provided dramatic new insight into the mechanisms of brain dysfunction in the disease, with a swathe of recent studies highlighting the differences in functional brain network and neural system connectivity present in the disorder. Only recently has the value of applying these approaches in preclinical rodent models relevant to the disorder started to be recognised. Here we highlight recent findings of altered functional brain connectivity in preclinical rodent models and consider their relevance to those alterations seen in the brains of schizophrenia patients. Furthermore, we highlight the potential translational value of using the paradigm of functional brain connectivity phenotypes in the context of preclinical schizophrenia drug discovery, as a means both to understand the mechanisms of brain dysfunction in the disorder and to reduce the current high attrition rate in schizophrenia drug discovery.

AB - While our knowledge of the pathophysiology of schizophrenia has increased dramatically, this has not translated into the development of new and improved drugs to treat this disorder. Human brain imaging and electrophysiological studies have provided dramatic new insight into the mechanisms of brain dysfunction in the disease, with a swathe of recent studies highlighting the differences in functional brain network and neural system connectivity present in the disorder. Only recently has the value of applying these approaches in preclinical rodent models relevant to the disorder started to be recognised. Here we highlight recent findings of altered functional brain connectivity in preclinical rodent models and consider their relevance to those alterations seen in the brains of schizophrenia patients. Furthermore, we highlight the potential translational value of using the paradigm of functional brain connectivity phenotypes in the context of preclinical schizophrenia drug discovery, as a means both to understand the mechanisms of brain dysfunction in the disorder and to reduce the current high attrition rate in schizophrenia drug discovery.

KW - EEG

KW - fMRI

KW - default mode network

KW - graph theory

KW - genetic risk factors

KW - hippocampal-prefrontal connectivity

KW - thalamic connectivity

KW - drug discovery

UR - http://jop.sagepub.com/content/29/2/169

U2 - 10.1177/0269881114563635

DO - 10.1177/0269881114563635

M3 - Article

C2 - 25567554

VL - 29

SP - 169

EP - 177

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 2

ER -